Craneware PLC (AIM:CRW) shares slumped 18%, trading down to 1,192p, after the firm warned full-year revenue and earnings will fall below market expectations after 340B pharmacy-related opportunities converted into recognised revenue more slowly than anticipated in the final weeks of the financial year.
The healthcare financial performance software group said revenue for the year to 30 June 2026 is expected to be between US$205mln and US$208mln, while adjusted EBITDA is forecast at US$65mln to US$67mln. Both are broadly in line with FY25.
Craneware said the shortfall reflected the timing of eligible 340B activity and the deferral of a small number of significant enterprise contracts, which are now expected to contribute during FY27. The final reported outcome remains subject to confirmation of eligible 340B activity recognised before year-end.
The company said it continues to see substantial opportunities for hospitals to optimise 340B programmes, with outstanding qualifying drug purchases of around US$500mln. However, the pace at which these translated into eligible drug purchases slowed materially as pharmaceutical manufacturers expanded restrictions on the supply of certain 340B-priced medicines.
Chief executive Keith Neilson said the company was “disappointed not to have delivered the growth that we expected in FY26”, but added that customer retention, demand and cash generation remained strong.
Craneware said it would provide a further update with full-year results in September 2026.
